Cargando…

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes

Oncolytic adenoviruses are promising cancer therapeutic agents. Clinical data have shown adenoviruses’ ability to transduce tumors after systemic delivery in human cancer patients, despite antibodies. In the present work, we have focused on the interaction of a chimeric adenovirus Ad5/3 with human l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zafar, Sadia, Quixabeira, Dafne Carolina Alves, Kudling, Tatiana Viktorovna, Cervera-Carrascon, Victor, Santos, Joao Manuel, Grönberg-Vähä-Koskela, Susanna, Zhao, Fang, Aronen, Pasi, Heiniö, Camilla, Havunen, Riikka, Sorsa, Suvi, Kanerva, Anna, Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119244/ https://www.ncbi.nlm.nih.gov/pubmed/32920593 http://dx.doi.org/10.1038/s41417-020-00226-z

Ejemplares similares

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
por: Pakola, Santeri, et al.
Publicado: (2023)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1
por: Cervera-Carrascon, Victor, et al.
Publicado: (2021)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer
por: Clubb, James H. A., et al.
Publicado: (2022)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
por: Clubb, James H. A., et al.
Publicado: (2023)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

Effective intravenous delivery of adenovirus armed with TNFα and IL-2 improves anti-PD-1 checkpoint blockade in non-small cell lung cancer
por: Kudling, Tatiana V., et al.
Publicado: (2023)

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
por: Havunen, Riikka, et al.
Publicado: (2021)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
por: Quixabeira, D. C. A., et al.
Publicado: (2023)

Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors
por: Tähtinen, Siri, et al.
Publicado: (2015)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
por: Tähtinen, Siri, et al.
Publicado: (2015)

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
por: Autio, Karoliina, et al.
Publicado: (2014)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells
por: Parviainen, Suvi, et al.
Publicado: (2015)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
por: Vähä-Koskela, Markus, et al.
Publicado: (2015)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
por: Hemminki, Kari, et al.
Publicado: (2022)

Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5
por: Ahonen, Marko T., et al.
Publicado: (2010)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
por: Ylösmäki, Erkko, et al.
Publicado: (2013)

Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism
por: Koski, Anniina, et al.
Publicado: (2013)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2018)

Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles
por: Autio, Karoliina P. M., et al.
Publicado: (2015)

Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression
por: López González, Marta, et al.
Publicado: (2019)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_4gceskqmo9dl41pt82eb35vk2g